473 filings
PRE 14A
VTGN
VistaGen Therapeutics Inc
Preliminary proxy
31 Dec 20
5:21pm
8-K
VTGN
VistaGen Therapeutics Inc
22 Dec 20
VistaGen Therapeutics Announces Closing of $100 Million Underwritten Public Offering
4:17pm
424B5
VTGN
VistaGen Therapeutics Inc
21 Dec 20
Prospectus supplement for primary offering
12:00am
FWP
VTGN
VistaGen Therapeutics Inc
18 Dec 20
Free writing prospectus
6:38am
424B5
VTGN
VistaGen Therapeutics Inc
17 Dec 20
Prospectus supplement for primary offering
5:13pm
8-K
o17xq
1 Dec 20
Other Events
4:24pm
8-K
0ztriw4ozfw s0
16 Nov 20
VistaGen Therapeutics Reports Fiscal 2021 Second Quarter Financial Results and Provides Highlights on its CNS Pipeline and Business Progress
12:00am
8-K
0qcr191big10h
13 Oct 20
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:06pm
SC 13G
u0sbga15wr6p
18 Sep 20
VistaGen Therapeutics / Rosalind Advisors ownership change
4:56pm
8-K
kueryi0zwehx 5s5663
18 Sep 20
2020 Virtual Annual Meeting of Stockholders
9:14am
4
3c2x7n4 0e0420a10o
24 Aug 20
VistaGen Therapeutics / JON S SAXE ownership change
4:31pm
8-K
x30ft3n ktix
14 Aug 20
VistaGen Therapeutics Reports Fiscal 2021 First Quarter Financial Results and Highlights CNS Pipeline and Business Progress
5:24pm
8-K
c8q3p4y6cbd2se6j
5 Aug 20
VistaGen Therapeutics Announces Pricing of $12.5 Million Underwritten Public Offering of Common Stock
9:56pm
424B5
gt4v3b3qzda8d k6
3 Aug 20
Prospectus supplement for primary offering
8:45pm
424B5
yzbgey1phr4r gbrjt
31 Jul 20
Prospectus supplement for primary offering
4:16pm
DEFA14A
xtey3dh5vfd
27 Jul 20
Additional proxy soliciting materials
4:52pm
8-K
rl27vl
24 Jul 20
Regulation FD Disclosure
6:03am